Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00920088 | Drug Interaction Study of Darunavir/Ritonavir and Lopinavir/Ritonavir on GSK2248761 PK and CYP450 Probe Drugs | PHASE1 | COMPLETED | 24 | — | — | Jun 1, 2009 | Nov 1, 2009 | Nov 3, 2010 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| Cohort 1 | EXPERIMENTAL | GSK2248761 with LPV/RTV arm and probes |
| Cohort 2 | EXPERIMENTAL | GSK2248761 with DRV/RTV |
| Name | Type | Description |
|---|---|---|
| darunavir/ritonavir | DRUG | DRV/RTV 600/100mg |
| lopinavir/ritonavir | DRUG | LPV/RTV 400/100mg |
| Midazolam | DRUG | Midazolam 3mg |
| Dextromethorphan | DRUG | Dextromethorphan 30mg |
| Flurbiprofen | DRUG | Flurbiprofen 50mg |
| GSK2248761 | DRUG | NNRTI under investigation |
Inclusion Criteria: * Healthy as determined by a responsible and experienced physician, based on a medical evaluation including medical history, physical examination, laboratory tests and cardiac monitoring. * Male or female between 18 and 50 years of age inclusive, at the time of signing the infor...